Tpa Treatment For Stroke: Who Benefits?

Tissue plasminogen activator (tPA) is the only FDA-approved medication for treating acute ischemic strokes, the most common type of stroke. While tPA has been available since 1996, studies have shown that the rates of its administration remain low. For instance, a study of 22,842 patients hospitalized with ischemic stroke in the United States between 2001 and 2006 found that only 2.40% received tPA treatment in 2006. However, there has been a significant increase in the use of tPA for stroke treatment over the years. The percentage of patients receiving tPA treatment increased from 0.87% in 2001 to 2.40% in 2006. More recent data from 2012 to 2018 also showed an increasing trend in tPA usage, with a significant rise from 6.3% to 11.8%. This increase in tPA utilization has led to improved patient outcomes, with a significant reduction in mortality rates among stroke patients.

tPA administration rates in the US increased from 0.87% in 2001 to 2.40% in 2006

The administration of tissue plasminogen activator (tPA) to treat acute ischaemic stroke has been approved in the US since 1996. However, despite its ability to improve patient outcomes, tPA administration rates have historically been low.

Indeed, among the 22,842 patients hospitalized with ischaemic stroke in the US between 2001 and 2006, tPA administration rates increased from just 0.87% in 2001 to 2.40% in 2006.

This increase in tPA administration rates may be due to the efforts of programmes such as Get With The Guidelines and Target: Stroke, which have sought to improve the speed of delivery of thrombolytic therapy to acute ischaemic stroke patients. By the third quarter of 2018, 75% of acute ischaemic stroke patients treated at 913 US hospitals in the Get With The Guidelines-Stroke programme received tPA within 60 minutes of their hospital arrival.

Despite this improvement, tPA administration rates remain low overall, and further efforts to improve appropriate administration are encouraged.

Older patients are less likely to receive tPA

The problems start early in the drug treatment process: older adults are frequently excluded from the clinical trials for the very medications meant to help them. Doctors also fail to recognize when standard medication doses are only appropriate for much younger patients. This results in overmedicalization, which is estimated to be one of the top five causes of death in those 65 and older.

A study of Medicare beneficiaries found that older age, female gender, non-White race, lower income, and lack of complementary insurance were all significantly related to a self-perception of problems with access to care. Another study found that older patients were less likely than younger patients to receive tPA.

The exact optimal rate of thrombolysis administration for stroke patients is unknown, as databases lack detailed information on factors that would preclude tPA administration, such as late timing of presentation and mild stroke symptoms. However, even among presumed eligible patients, tPA administration rates only range between 25% and 43%.

Ageism in health care is a serious issue that can lead to harmful consequences for older patients. It is important to address this problem through changes in medical training and attitudes to ensure that older adults receive the care they need.

Mechanical thrombectomy (MT) is now a first-line treatment for select patients with acute ischemic stroke

The establishment of MT as a first-line treatment for acute ischemic stroke and the expansion of stroke systems of care have been major advancements in patient care. Between 2012 and 2018, the use of MT increased significantly, from 1.6% to 5.7% of patients presenting with acute ischemic stroke. The most dramatic decrease in mortality was seen in the MT-treated population.

MT is the most effective treatment for large vessel occlusion (LVO) and has many advantages compared to thrombolysis in LVO stroke. MT with newer thrombectomy devices has been shown to be superior to the best medical management using intravenous thrombolysis. MT can be used in conjunction with intravenous tissue plasminogen activator (IV tPA) but has also shown benefits after the 4.5-hour tPA window, making it an option for patients who are ineligible for tPA.

MT is a safe treatment and is equally effective for both anterior circulation and posterior circulation LVO. MT can also be successfully applied to basilar artery occlusion, which is associated with a very poor outcome. MT achieves high revascularization rates and good functional outcomes in patients with AIS and large artery occlusion.

Overall, MT is a safe and effective treatment for select patients with acute ischemic stroke, improving clinical outcomes and reducing mortality.

The use of tPA and MT has increased significantly, and mortality rates have decreased

The use of tissue plasminogen activator (tPA) and mechanical thrombectomy (MT) has increased significantly in recent years, and mortality rates have decreased. tPA is the only medication approved to treat acute ischemic strokes, the most common form of stroke, and has been available since 1996. MT was established as a first-line treatment for select patients with acute ischemic stroke (AIS) in 2015.

The percentage of AIS patients receiving tPA increased from 0.87% in 2001 to 2.40% in 2006, and further increased to 11.8% in 2018. The use of MT also increased significantly during this time, from 1.6% in 2012 to 5.7% in 2018. This increase in treatment has led to a decrease in mortality rates, with the most dramatic decrease seen in the MT-treated population.

The increased use of tPA and MT is likely due to the establishment of primary and comprehensive stroke centers, improved organization of stroke care, and increased awareness and education among clinicians and the public. These advancements have resulted in more timely and effective treatment for stroke patients, leading to improved outcomes and reduced mortality rates.

However, it is important to note that the use of tPA and MT is still underutilized, and further efforts are needed to improve appropriate administration rates, especially as the acceptable time window for using tPA widens. Additionally, there may be other factors contributing to the decrease in mortality rates, such as differences in hospital presentation, diagnosis, admission/discharge practices, or coding practices. Further investigations are necessary to fully understand the factors contributing to these trends.

tPA is the only FDA-approved drug to treat acute ischemic strokes

Intravenous tissue plasminogen activator (tPA), also known as IV-tPA or Alteplase, is the only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute ischemic strokes. It is a thrombolytic agent, or clot-busting drug, that works by dissolving blood clots that block blood flow to the brain.

TPA was first approved by the FDA for the treatment of acute ischemic stroke in 1996, following clinical trials that demonstrated its safety and efficacy. Since then, it has become the mainstay of early treatment for acute ischemic strokes, with its use increasing significantly over the years. However, despite its proven efficacy, tPA remains underutilized, with only a small percentage of stroke patients receiving the drug.

The administration of tPA within three hours of the onset of stroke symptoms is crucial to improving outcomes. It can significantly reduce the effects of a stroke and decrease long-term disability. However, not all patients qualify for tPA treatment, and it carries a risk of severe intracranial hemorrhage. Therefore, careful patient selection and assessment of eligibility criteria are essential.

The expansion of the time window for tPA eligibility from three to 4.5 hours after stroke onset and revisions to the contraindications have promoted increased utilization of the drug. Additionally, the development of regional systems of stroke care, including primary and comprehensive stroke centers, has improved access to timely and appropriate treatment.

Frequently asked questions